150 related articles for article (PubMed ID: 31255601)
1. ADP-ribosylation inhibitors in treatment of diseases.
Bai P; Poltronieri P; Di Girolamo M
Biochem Pharmacol; 2019 Sep; 167():1-2. PubMed ID: 31255601
[No Abstract] [Full Text] [Related]
2. Small-Molecule Inhibitors of PARPs: From Tools for Investigating ADP-Ribosylation to Therapeutics.
Kirby IT; Cohen MS
Curr Top Microbiol Immunol; 2019; 420():211-231. PubMed ID: 30242511
[TBL] [Abstract][Full Text] [Related]
3. Enabling drug discovery for the PARP protein family through the detection of mono-ADP-ribosylation.
Lu AZ; Abo R; Ren Y; Gui B; Mo JR; Blackwell D; Wigle T; Keilhack H; Niepel M
Biochem Pharmacol; 2019 Sep; 167():97-106. PubMed ID: 31075269
[TBL] [Abstract][Full Text] [Related]
4. Host poly(ADP-ribose) polymerases (PARPs) in acute and chronic bacterial infections.
Miettinen M; Vedantham M; Pulliainen AT
Microbes Infect; 2019 Dec; 21(10):423-431. PubMed ID: 31207286
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-Ribosylation) in Age-Related Neurological Disease.
McGurk L; Rifai OM; Bonini NM
Trends Genet; 2019 Aug; 35(8):601-613. PubMed ID: 31182245
[TBL] [Abstract][Full Text] [Related]
6. Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders.
Faraoni I; Giansanti M; Voso MT; Lo-Coco F; Graziani G
Biochem Pharmacol; 2019 Sep; 167():133-148. PubMed ID: 31028744
[TBL] [Abstract][Full Text] [Related]
7. New Quantitative Mass Spectrometry Approaches Reveal Different ADP-ribosylation Phases Dependent On the Levels of Oxidative Stress.
Bilan V; Selevsek N; Kistemaker HAV; Abplanalp J; Feurer R; Filippov DV; Hottiger MO
Mol Cell Proteomics; 2017 May; 16(5):949-958. PubMed ID: 28325851
[TBL] [Abstract][Full Text] [Related]
8. NADP
Bian C; Zhang C; Luo T; Vyas A; Chen SH; Liu C; Kassab MA; Yang Y; Kong M; Yu X
Nat Commun; 2019 Feb; 10(1):693. PubMed ID: 30741937
[TBL] [Abstract][Full Text] [Related]
9. Targeting ADP-ribosylation as an antimicrobial strategy.
Catara G; Corteggio A; Valente C; Grimaldi G; Palazzo L
Biochem Pharmacol; 2019 Sep; 167():13-26. PubMed ID: 31176616
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response.
Francica P; Rottenberg S
Genome Med; 2018 Dec; 10(1):101. PubMed ID: 30593284
[TBL] [Abstract][Full Text] [Related]
11. PARP inhibitors in ovarian and other cancers.
Plummer R
Clin Adv Hematol Oncol; 2015 May; 13(5):285-7. PubMed ID: 26352770
[No Abstract] [Full Text] [Related]
12. Poly(ADP-ribosylation) and neoplastic transformation: effect of PARP inhibitors.
Donà F; Chiodi I; Belgiovine C; Raineri T; Ricotti R; Mondello C; Scovassi AI
Curr Pharm Biotechnol; 2013; 14(5):524-36. PubMed ID: 22429135
[TBL] [Abstract][Full Text] [Related]
13. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
Rabenau K; Hofstatter E
Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
[TBL] [Abstract][Full Text] [Related]
14. Detecting Protein ADP-Ribosylation Using a Clickable Aminooxy Probe.
Morgan RK; Cohen MS
Methods Mol Biol; 2017; 1608():71-77. PubMed ID: 28695504
[TBL] [Abstract][Full Text] [Related]
15. Studying Catabolism of Protein ADP-Ribosylation.
Palazzo L; James DI; Waddell ID; Ahel I
Methods Mol Biol; 2017; 1608():415-430. PubMed ID: 28695524
[TBL] [Abstract][Full Text] [Related]
16. New insights of poly(ADP-ribosylation) in neurodegenerative diseases: A focus on protein phase separation and pathologic aggregation.
Liu C; Fang Y
Biochem Pharmacol; 2019 Sep; 167():58-63. PubMed ID: 31034795
[TBL] [Abstract][Full Text] [Related]
17. Structural Requirements of Some 2-(1-Propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide Derivatives as Poly (ADP-Ribose) Polymerase (PARP) for the Treatment of Cancer: QSAR Approach.
Sharma MC
Interdiscip Sci; 2016 Mar; 8(1):11-22. PubMed ID: 26205198
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of PARP inhibitor sensitivity and resistance.
D'Andrea AD
DNA Repair (Amst); 2018 Nov; 71():172-176. PubMed ID: 30177437
[TBL] [Abstract][Full Text] [Related]
19. ADP-Ribosylated Peptide Enrichment and Site Identification: The Phosphodiesterase-Based Method.
Daniels CM; Ong SE; Leung AKL
Methods Mol Biol; 2017; 1608():79-93. PubMed ID: 28695505
[TBL] [Abstract][Full Text] [Related]
20. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
Jain PG; Patel BD
Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
